The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Cephalon, U.S. States Reach $125 Million Settlement Over Generic Drugs

Cephalon, U.S. States Reach $125 Million Settlement Over Generic Drugs

August 6, 2016 • By Sarah N. Lynch

  • Tweet
  • Email
Print-Friendly Version / Save PDF

WASHINGTON (Reuters)—Cephalon has reached a $125 million settlement with 48 states in connection with its alleged efforts to delay generic versions of its blockbuster sleep disorder drug modafinil (Provigil) from entering the market, New York Attorney General Eric Schneiderman said on Thursday.

You Might Also Like
  • U.S. Tribal Patent Deal Could Impact Generic Drug Market
  • Pfizer Unit to Pay $784.6 Million in Medicaid Rebate Settlement
  • U.S. House Panel Spotlights Use of FDA Rules to Slow Generic Drugs

The settlement with Cephalon, now owned by Teva Pharmaceuticals, comes a little more than a year after the company struck a $1.2 billion parallel settlement with the Federal Trade Commission.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The FTC accused the company of protecting its monopoly on Provigil by paying generic drug makers to drop their challenges to Cephalon’s patent, in what is known as a “pay-for-delay” deal.

A company spokeswoman said Thursday’s settlement resolves litigation with the states in connection with “an 11-year-old settlement between Cephalon and various other companies.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“It will be funded from the proceeds of the settlement entered into in 2015 between Cephalon and the FTC,” she added.

In a statement, Schneiderman said Cephalon defrauded the Patent and Trademark Office in order to secure an additional patent, which was later invalidated by a court.

At the same time, the company successfully delayed generic competition of the drug by six years through filing patent infringement lawsuits and then settling them by paying competitions to delay selling generic versions of Provigil, Schneiderman said.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“When pharmaceutical companies put profits ahead of people by illegally restricting competition, it harms patients across our state,” Schneiderman said.

“This misconduct which drives up the cost of prescription drugs will not be tolerated.”

The settlement is still subject to court review.

Filed Under: Drug Updates, Legal, Pharma Co. News Tagged With: generic drugs, lawsuit, Legal, Teva Pharmaceuticals

You Might Also Like:
  • U.S. Tribal Patent Deal Could Impact Generic Drug Market
  • Pfizer Unit to Pay $784.6 Million in Medicaid Rebate Settlement
  • U.S. House Panel Spotlights Use of FDA Rules to Slow Generic Drugs
  • U.S. Appeals Court Ruling May Clear Barrier to Generic OxyContin

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)